Mandrioli, R.; Mercolini, L.; Raggi , M. A. (2008). “Benzodiazepine Metabolism: An Analytical Perspective”. Current Drug Metabolism9 (8): 827–844. doi:10.2174/138920008786049258. PMID18855614.
Closser, Mh; Brower, Kj (July 1994). “Treatment of alprazolam withdrawal with chlordiazepoxide substitution and taper.”. Journal of substance abuse treatment11 (4): 319?23. doi:10.1016/0740-5472(94)90042-6. PMID7966502.
drugs.com
“Alprazolam”. The American Society of Health-System Pharmacists. 2011年5月15日時点のオリジナルよりアーカイブ。2011年3月15日閲覧。
fda.gov
accessdata.fda.gov
“FDA approved labeling for Xanax revision 08/23/2011” (PDF). Federal Drug Administration. p. 4 (2011年8月23日). 2011年9月14日閲覧。 “Anxiety Disorders – XANAX Tablets (alprazolam) are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSMIII-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic... Panic Disorder – XANAX is also indicated for the treatment of panic disorder, with or without agoraphobia... Demonstrations of the effectiveness of XANAX by systematic clinical study are limited to 4 months duration for anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis without any apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient.”
Mandrioli, R.; Mercolini, L.; Raggi , M. A. (2008). “Benzodiazepine Metabolism: An Analytical Perspective”. Current Drug Metabolism9 (8): 827–844. doi:10.2174/138920008786049258. PMID18855614.
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ (2002). “World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders”. World J. Biol. Psychiatry3 (4): 171–99. PMID12516310.
Lydiard, Rb; Laraia, Mt; Ballenger, Jc; Howell, Ef (May 1987). “Emergence of depressive symptoms in patients receiving alprazolam for panic disorder”. The American journal of psychiatry144 (5): 664–5. PMID3578580.
Juergens, Sm; Morse, Rm (May 1988). “Alprazolam dependence in seven patients.”. The American journal of psychiatry145 (5): 625?7. PMID3258735.
Klein, E (2002). “The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam.”. The Journal of clinical psychiatry63 (Suppl 14): 27?33. PMID12562116.
Closser, Mh; Brower, Kj (July 1994). “Treatment of alprazolam withdrawal with chlordiazepoxide substitution and taper.”. Journal of substance abuse treatment11 (4): 319?23. doi:10.1016/0740-5472(94)90042-6. PMID7966502.
Tesar GE (1990). “High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience”. J Clin Psychiatry51 (Suppl): 4?10; discussion 50-3. PMID1970816.
